Search results
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Reuters via Yahoo Finance· 2 weeks ago(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing...
COVID-19 vaccines: CDC says people ages 65 and up should get a shot this spring – a geriatrician...
The Conversation via Yahoo News· 2 months agoEven if you got a COVID-19 shot last fall, the spring shot is still essential for the 65 and up age...
Largest multicountry COVID study links vaccines to potential adverse effects
The Hill via Yahoo News· 3 months agoA new study on COVID-19 vaccines that looked at nearly 100 million vaccinated individuals affirmed...
Why It Took So Long to Finally Get an RSV Vaccine
Time via Yahoo News· 1 year agoCredit - Getty Images; GSK Respiratory syncytial virus (RSV) can dangerously compromise breathing, especially for infants and the elderly. But there has...
Shingles Vaccine Market is Booming in Near Future 2023-2031
NewMediaWire via Yahoo Finance· 1 year agoPune, India - (NewMediaWire) - March 3, 2023 - "Shingles Vaccine" Size, Scope, and Forecast...
FTSE 100: GSK tops forecasts after strong sales of shingles vaccine
Yahoo Finance UK· 1 year agoGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado...
2 Dividend Stocks to Double Up On Right Now
Motley Fool· 2 years agoAbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) have much in common. They are huge pharmaceutical companies that have a long record of success,...
These Are the Shots You Should Get This Fall and Winter
Time via Yahoo News· 8 months agoIt used to be relatively easy and straightforward to navigate the fall and winter respiratory...
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
Investor's Business Daily· 2 years agoSanofi stock bounded higher Friday after its GSK-partnered Covid shot tamped down omicron infections...
Moderna's Earnings Collapsed. Time to Sell?
Motley Fool· 2 years agoWhen it rains, it pours. Instead of a slow slide, COVID-19 vaccine sales at Moderna (NASDAQ: MRNA) collapsed in the third quarter. Investors who were...
